The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

NCT05702983 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Antineutrophil Cytoplasmic Antibody Associated Vasculitis

Interventions

DRUG: STSA-1002 subcutaneous injection
DRUG: STSA-1002 subcutaneous injection

Sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd